The reversible factor Xa inhibitor rivaroxaban (Xarelto®) is approved by the FDA for reducing the risk of stroke and systemic embolism in patients with nonvalvular AF and for treatment and prophylaxis of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery [33]. The gene discussed is F10; the disease is Stroke.